Improving how prevention is delivered
Once approved, interventions typically become widely available in wealthy countries within a few years time. But scaling up new options in lower and middle-income countries lags for years, even decades, with devastating effects on global health, individual lives, and the global effort to end the epidemic.
AVAC’s work supports:
infographic
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.
report
The latest issue presents new research on the effectiveness of oral PrEP in cisgender women, new injectable cabotegravir approvals and rollout, and much more!
infographic
To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable cabotegravir.
The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1 and PURPOSE 2.
Integrating PrEP and contraception in a single pill to expand choices.
A one-stop online clearinghouse for resources and information to help the global community effectively deliver proven methods of PrEP to everyone who needs it.
Overcoming access challenges to new PrEP options.
SAVE THE DATE: Join AVAC, Gilead and partners for a discussion of and comprehensive presentation on lenacapavir for PrEP data from the PURPOSE I and II trials, along with an update on where we are with global access and regulatory submissions.
More details, including registration, to come.